WallStSmart

Align Technology Inc (ALGN)vsAstraZeneca PLC (AZN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AstraZeneca PLC generates 1376% more annual revenue ($60.44B vs $4.10B). AZN leads profitability with a 17.2% profit margin vs 10.5%. ALGN appears more attractively valued with a PEG of 0.92. ALGN earns a higher WallStSmart Score of 66/100 (B-).

ALGN

Strong Buy

66

out of 100

Grade: B-

Growth: 6.0Profit: 6.5Value: 8.0Quality: 7.0
Piotroski: 4/9Altman Z: 2.76

AZN

Buy

64

out of 100

Grade: C+

Growth: 6.0Profit: 8.5Value: 6.0Quality: 5.0
Piotroski: 6/9Altman Z: 1.48
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ALGNUndervalued (+32.7%)

Margin of Safety

+32.7%

Fair Value

$293.37

Current Price

$167.74

$125.63 discount

UndervaluedFair: $293.37Overvalued
AZNUndervalued (+10.1%)

Margin of Safety

+10.1%

Fair Value

$194.57

Current Price

$185.95

$8.62 discount

UndervaluedFair: $194.57Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ALGN4 strengths · Avg: 8.5/10
Debt/EquityHealth
0.0310/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.928/10

Growing faster than its price suggests

Price/BookValuation
2.9x8/10

Reasonable price relative to book value

EPS GrowthGrowth
23.9%8/10

Earnings expanding 23.9% YoY

AZN4 strengths · Avg: 8.8/10
Market CapQuality
$282.69B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
21.9%9/10

Every $100 of equity generates 22 in profit

Operating MarginProfitability
27.9%8/10

Strong operational efficiency at 27.9%

Free Cash FlowQuality
$1.82B8/10

Generating 1.8B in free cash flow

Areas to Watch

ALGN1 concerns · Avg: 4.0/10
P/E RatioValuation
29.4x4/10

Moderate valuation

AZN2 concerns · Avg: 3.0/10
P/E RatioValuation
27.5x4/10

Moderate valuation

Altman Z-ScoreHealth
1.482/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : ALGN

The strongest argument for ALGN centers on Debt/Equity, PEG Ratio, Price/Book. PEG of 0.92 suggests the stock is reasonably priced for its growth.

Bull Case : AZN

The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.

Bear Case : ALGN

The primary concerns for ALGN are P/E Ratio.

Bear Case : AZN

The primary concerns for AZN are P/E Ratio, Altman Z-Score.

Key Dynamics to Monitor

ALGN profiles as a value stock while AZN is a mature play — different risk/reward profiles.

ALGN carries more volatility with a beta of 1.67 — expect wider price swings.

AZN is growing revenue faster at 12.5% — sustainability is the question.

AZN generates stronger free cash flow (1.8B), providing more financial flexibility.

Bottom Line

ALGN scores higher overall (66/100 vs 64/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Align Technology Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Align Technology is a manufacturer of 3D digital scanners and the Invisalign clear aligners used in orthodontics. It is headquartered in San Jose, California.

AstraZeneca PLC

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.

Want to dig deeper into these stocks?